Published in Bone on February 08, 2007
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int (2010) 0.97
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int (2008) 0.91
Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med (2013) 0.87
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Clinical role of bisphosphonate therapy. Int J Womens Health (2012) 0.85
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int (2009) 0.85
Micro-morphological properties of osteons reveal changes in cortical bone stability during aging, osteoporosis, and bisphosphonate treatment in women. Osteoporos Int (2013) 0.83
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.80
Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence. Int J Womens Health (2015) 0.79
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. Osteoporos Int (2009) 0.79
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. J Bone Miner Res (2012) 0.79
Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats. Osteoporos Int (2013) 0.78
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.78
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interv Aging (2008) 0.77
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging (2008) 0.77
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid. Patient Prefer Adherence (2009) 0.76
Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med (2009) 0.76
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. Ther Clin Risk Manag (2009) 0.75
Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion. Exp Ther Med (2017) 0.75
Burn wound infections. Clin Microbiol Rev (2006) 4.81
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med Genet (2006) 2.25
Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline. Am J Kidney Dis (2013) 2.07
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol (2012) 1.88
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res (2002) 1.44
Males have larger skeletal size and bone mass than females, despite comparable body size. J Bone Miner Res (2004) 1.42
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res (2005) 1.42
Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Menopause (2011) 1.40
Structure of clean and adsorbate-covered single-crystal rutile TiO2 surfaces. Chem Rev (2013) 1.40
Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab (2003) 1.38
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res (2005) 1.33
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care (2008) 1.30
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Chemical reactions on rutile TiO2(110). Chem Soc Rev (2008) 1.26
Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. Diabetes Care (2012) 1.25
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 1.19
Relation of lower-extremity amputation to all-cause and cardiovascular disease mortality in American Indians: the Strong Heart Study. Diabetes Care (2004) 1.12
Health professional's guide to rehabilitation of the patient with osteoporosis. Osteoporos Int (2003) 1.11
Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. J Clin Densitom (2003) 1.10
Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol (2003) 1.09
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc (2002) 1.07
Vitamin D economy in blacks. J Bone Miner Res (2007) 1.05
Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. J Bone Miner Res (2007) 1.03
Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab (2005) 1.03
Laser Doppler imaging of burn scars: a comparison of wavelength and scanning methods. Burns (2003) 1.00
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res (2009) 0.99
Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab (2014) 0.98
Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. J Am Geriatr Soc (2010) 0.98
Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone (2006) 0.96
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96
Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc (2012) 0.95
Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem (2005) 0.95
Canadian Society of Nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis. Am J Kidney Dis (2013) 0.94
Big mother or small baby: which predicts hypertension? J Clin Hypertens (Greenwich) (2010) 0.94
Double and quadruple tetracycline labeling of bone: impact of the label itself. J Bone Miner Res (2013) 0.92
Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2013) 0.92
Determinants of stress fracture risk in United States Military Academy cadets. Bone (2013) 0.91
Influence of nitrogen fertilization on xylem traits and aquaporin expression in stems of hybrid poplar. Tree Physiol (2010) 0.91
Blood pressure, volume, and sodium control in an automated peritoneal dialysis population. Perit Dial Int (2007) 0.90
Patient experiences and preferences on short daily and nocturnal home hemodialysis. Hemodial Int (2012) 0.87
The effects of hormone replacement on the biomechanical properties of the uterosacral and round ligaments in the monkey model. Am J Obstet Gynecol (2005) 0.84
The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology (2007) 0.84
Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. J Bone Miner Res (2012) 0.84
Vascular access for intensive maintenance hemodialysis: a systematic review for a Canadian Society of Nephrology clinical practice guideline. Am J Kidney Dis (2013) 0.84
Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. Am J Obstet Gynecol (2007) 0.83
Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. J Bone Miner Res (2005) 0.83
Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW). Calcif Tissue Int (2014) 0.83
Screening for depression in chronic hemodialysis patients: comparison of the Beck Depression Inventory, primary nurse, and nephrology team. Hemodial Int (2006) 0.82
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials. J Womens Health (Larchmt) (2008) 0.82
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int (2003) 0.82
Euvolemia in hemodialysis patients: a potentially dangerous goal? Semin Dial (2014) 0.81
One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients. Curr Med Res Opin (2010) 0.80
The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadets. Nutr Metab (Lond) (2007) 0.79
Therapeutic potential of parathyroid hormone. Curr Osteoporos Rep (2004) 0.79
Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen. Calcif Tissue Int (2012) 0.77
The nutritional status of chronic renal failure patients following the initiation of hemodialysis treatment. Am J Kidney Dis (2002) 0.77
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int (2004) 0.77
Calcium and fracture risk. Am J Clin Nutr (2007) 0.75
Urinary free (unconjugated) metadrenalines in different hereditary forms of catecholamine-secreting phaeochromocytoma/paraganglioma. Ann Clin Biochem (2012) 0.75
The Effect of Increased Frequency of Hemodialysis on Volume-Related Outcomes: A Secondary Analysis of the Frequent Hemodialysis Network Trials. Blood Purif (2016) 0.75
Renewing focus and building capacity for enacting authentic collaboration in work rehabilitation. Work (2008) 0.75
What have we learned from clinical studies? Fractures and the interactions of bone mass and remodeling. Osteoporos Int (2003) 0.75
Occult malignancy rate associated with thoracodorsal vessel dissection for free flap breast reconstruction. J Surg Oncol (2008) 0.75
Abortion: is it the law's business? Spectator (1974) 0.75